How many times have you treated eczema flare-ups — only for them to return again?
Many people believe they simply have “weak immunity” or a “sensitive body.”
But what if the real issue is something deeper — a persistent, disease-associated gut dysbiosis that was never properly corrected?
Most probiotics on the market are broad and general. They may temporarily support gut health or reduce inflammation. But they are not designed to correct the specific dysbiosis pattern driving a particular disease.
That is why symptoms improve — but eventually return
G-NiiB was built on a different philosophy:
- Identify the specific gut dysbiosis linked to a disease.
- Correct it precisely.
- Break the recurrence cycle.
- Reduce severity over time.
This is not symptom management.
This is microbiome correction at the disease-biology level.
Why G-NiiB Is Different
Scientists and clinicians at a renowned university in Hong Kong used Metagenomics-Driven AI technology to map gut bacteria patterns in thousands of patients.

They identified:
• The harmful bacteria driving disease
• The protective bacteria that were missing
• The exact imbalance sustaining recurrence

These insights led to the development of targeted microbiome correction formulas – each designed to address a specific disease-associated dysbiosis pattern.
Because when the dysbiosis is corrected, the recurrence cycle can be reduced.
Early-Life Persistent Eczema and the Gut-Skin Axis

Childhood eczema is increasingly recognised as more than a skin condition.
Emerging research shows that early-life gut dysbiosis can influence immune development, skin barrier maturation, and inflammatory regulation.
In many children, eczema improves temporarily with topical steroids or moisturisers – yet flare-ups recur.
This pattern suggests that while surface inflammation is suppressed, the underlying immune dysregulation may persist.
Studies have shown that children with eczema often exhibit:
- Reduced beneficial gut bacteria
- Altered immune-modulating microbial metabolites
- Increased inflammatory signalling
This imbalance along the Gut-Skin Axis may contribute to recurring flare cycles.
G-NiiB Immune Kids SIM03 – Targeted Early Microbiome Correction

G-NiiB Immune Kids SIM03 was developed to address disease-associated gut dysbiosis observed in childhood eczema.
By restoring key immune-regulating bacteria and supporting healthier gut barrier function, SIM03 helps:
- Support balanced immune development
- Modulate inflammatory response
- Strengthen gut-skin communication
- Reduce recurrence tendency over time
G-NiiB Immune Kids SIM03 is not a steroid replacement. It is a targeted microbiome approach designed to support long-term immune stability from the gut.

Here’s a snapshot of how G-Niib Immune Kids SIM03 works to correct gut dysbiosis and provide much-needed and sustained relief, unlike other treatments.

Recurring conditions often reflect unresolved microbiome imbalance.
When disease-associated gut dysbiosis is left uncorrected, symptoms may improve temporarily – but the cycle continues.
G-NiiB’s targeted Immune Kids SIM03 formulation is designed to address the specific gut-skin axis, supporting microbiome correction at the biological level.
With consistent use, this precision approach helps reduce recurring skin flare-ups in babies and children, and promotes greater long-term stability.
Choose G-NiiB Immune Kids SIM03 today, and support your body from the root.